Investment portfolio (30/06/2024).
We provide smart capital for Belgian innovation and driving socio-economic growth.
Our role is to create
sustainable long-term value.
all our investments are driven by our values.
MINORYX THERAPEUTICS
Détention du capital6 %
Minoryx Therapeutics is a Spanish biotech company that focuses its research on the development of treatments against orphan diseases affecting the central nervous system. The company developed a molecule that has been shown to be safe and effective in humans in the context of a genetic neurodegenerative disorder.
MIRACOR MEDICAL
Détention du capital8.77 %
Miracor is active in the medical devices sector. In particular it has developed a technique now being used to treat heart infarcts to ensure that fewer heart cells die in the heart’s left-hand chamber. This prevents repeat heart failures which typically occur among 25% of all treated patients.
NANOCYL (sold nov 2023)
Détention du capital6.97 %
The company has as its aim the design, development, production and marketing of carbon nanotubes and carbon nanotubes formulated products.
LOTERIE NATIONALE
Détention du capital21.28 %
This company organises public lotteries, betting and competitions.
NCARDIA BELGIUM
Détention du capital8.7 %
Ncardia has developed a process for producing induced pluripotent stem cells (IPSC) and produces cardiac muscle cells or cardiac myocytes. Induced pluripotecy is the 'reprogramming' of a differentiated cell in a stem cell by reactivating the expression of the genes associated with the embryonic stage.
NECKERMANN BELGIUM
Détention du capital0.00 %
Company that allows you to book holidays
NEUVASQ BIOTECHNOLOGIES
Détention du capital11.36 %
Company that manufactures pharmaceutical products for acute neurological disorders.
NEWTON BIOCAPITAL I
Détention du capital17.67 %
The fund was created in April 2017 as a private Pricaf [investment vehicle for private equity investments] and targets companies active in the treatment of chronic diseases such as inflammatory, neurodegenerative, cardiovascular disease and cancer. The fund is geared to Belgian companies as well as European "early stage" companies such as university spin-offs.
NEWTON BIOCAPITAL II
Détention du capital19 %
The fund was created in April 2017 in the form of a private Pricaf and targets companies active in the treatment of chronic diseases such as inflammatory, neurodegenerative, cardiovascular and cancer. The fund is aimed at Belgian companies as well as European "early stage" companies such as university spin-offs.
NORMANDY HADRONTHERAPY/NHA (IBA)
Détention du capital9.77 %
The technological solution proposed by Normandy Hadrontherapy aims to make hadrontherapy (proton therapy and carbon beam treatment) more accessible to clinical treatment centres. The technological solution proposed by NHa aims to replace the synchrotron with an isochronous cyclotron, which is a more compact piece of equipment, significantly less expensive and easier to operate and maintain than the synchrotons currently in use.
NUCLEIS
Détention du capital17.20 %
Nucleis specialises in the production in a GMP environment of radiopharmaceutical medicines for human use (including nuclear and non-nuclear medical imaging). It is the result of a spin-off process of the Cyclotron Research Centre of the University of Liege.
NXTPORT
Détention du capital24.57 %
NxtPort manages a data platform used to collect, group and then centralise data of the different links in the logistical supply chain related to activities in the Port of Antwerp. The platform is designed to improve the sharing of data, thus enhancing the transparency and efficiency of this process.
OMXE INVEST
Détention du capital12.95 %
Company that manages public APCO under Belgian or foreign law.
OMXE PARTNERS
Détention du capital16.67 %
ONCO DNA
Détention du capital17.81 %
The company is active in the genetic and protein characterisation of tissue samples sent for analysis by oncologists. It was incorporated in December 2012 and benefits from strong cooperation with the Institute of Genetic Pathology -- a cooperation that has avoided the need for heavy investment in medical analysis.
OPEN SKY TECHNOLOGIES FUND BELGIUM POOL
Détention du capital0.00 %
Company that focuses on seed capital investments.